Sungkyunkwan University · 医学
Professor Hyun Ae Jung's research spans computational optimization and biomedical oncology, with a focus on algorithmic efficiency in multiprocessor scheduling for directed acyclic graphs (DAGs) with communication delays, as well as clinical research in cancer treatment. Her work includes investigating targeted therapies and chemotherapy regimens in advanced or recurrent cancers, particularly nasopharyngeal carcinoma and urothelial cancer, with an emphasis on efficacy, survival outcomes, and central nervous system involvement. She also explores the impact of systemic therapies like capecitabine and immunotherapy combinations on treatment-related toxicities and long-term outcomes. Her interdisciplinary approach bridges theoretical computer science and clinical oncology, aiming to improve both computational resource allocation and patient survival strategies.
Figures are computed from collected data and may differ slightly.
Article Free Access Share on Lower bounds and efficient algorithms for multiprocessor scheduling of dags with communication delays Authors: H. Jung Mathematics Dept., Humboldt Univ., GDR Mathematics Dept., Humboldt Univ., GDRView Profile , L. Kirousis Computer Technology Institute, Patras Univ., Greece Computer Technology Institute, Patras Univ., GreeceView Profile , P. Spirakis Computer Technology Institute, Patras Univ., Greece and Courant Inst. Math. Sciences, NYU Computer Technology Institut
In urachal cancer, curative surgery is still the recommended treatment with respect to overall survival. A 5-FU-based chemotherapy regimen could be considered for metastatic recurrent disease.
Through there are some limitation as a retrospective study, afatinib showed similar CNS response rates, superior CNS-PFS and cumulative incidence of CNS failure, compared with gefitinib or erlotinib.
Nivolumab plus gemcitabine showed promising efficacy with favorable toxicity profiles in patients with advanced NPC in whom platinum-based combination chemotherapy failed.
Optical gain spectra of GaInAsP/InP double heterostructures (DHs) have been recorded in the temperature range of 80–300 K. These data are compared with threshold currents of DHs injection lasers fabricated from the same wafers. An identical behavior of maximum optical gain and threshold current is observed, i.e., two T0 values (100 and 63 K) with a break-point temperature of TB ≃260 K are found. Furthermore, characteristic changes of the optical gain spectrum are observed close to the break-poin
Macrocytosis developed with more frequent and prolonged use of capecitabine. It is possible that association with treatment outcomes warrants further investigation.
The low-risk group with TRU subtype and TP53 wild-type without clinicopathologic risk factors might not need adjuvant EGFR-TKIs. In the high-risk group, with non-TRU subtype and/or TP 53 mutation, or clinicopathologic risk factors, a novel adjuvant strategy of EGFR-TKI with others, e.g., chemotherapy or antiangiogenic agents needs to be investigated. Given the poor outcome to EGFR-TKIs after recurrence in patients with the APOBEC mutation signature, an alternative adjuvant strategy might be need
Open papers in the app to read, cite, and organize with AI.
